百时美施贵宝 BMY

Mr. Christopher S. Boerner, Experience: Bristol Myers Squibb, Chief Executive Officer (November 2023-present); Board Chair (April 2024-present); Board Member (2023-present); Executive Vice President, Chief Operating Officer (April 2023-October 2023); Executive Vice President, Chief Commercialization Officer (2018-2023); Head of International Markets (2017-2018); Head of U.S. Commercial Markets (2015-2017); Held leadership roles of increasing responsibility at Seattle Genetics, Inc. (2010-2015); Served in marketing leadership roles at Genentech (2002-2010); Worked at McKinsey & Company, earlier in his career, serving global pharmaceutical and biotechnology clients. Other Public Company Boards: Colgate-Palmolive Company. Other: Board of Directors of PhRMA (Pharmaceutical Research and Manufacturers of America); Board member, Chair of the Nominating and Corporate Governance Committee of Achaogen, Inc. (2014-2015).

Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi, 2019 to 2020 - Senior Vice President, Head of Oncology Late Development, Astra Zeneca; 2021 to 2025 - Chief Medical Officer, Oncology Chief Development Officer, AstraZeneca; 2025 to present - Executive Vice President, Chief Medical Officer, Head of Development.

Mr. Adam Lenkowsky, 2016 to 2019 - Head of US Oncology; 2019 to 2022 - Senior Vice President, General Manager of U.S. Oncology, Immunology & Cardiovascular; 2022 to 2023 Senior Vice President, Head of Major Markets; 2023 to present - Executive Vice President, Chief Commercialization Officer.

Mr. David V. Elkins, 2014 to 2017 - Group Vice President and Chief Financial Officer, Consumer and Consumer Medicines, Johnson & Johnson; 2017 to 2018 - Worldwide Vice President and Chief Financial Officer, Consumer Products, Medical Development and Corporate Functions, Johnson & Johnson; 2018 to 2019 - Chief Financial Officer, Celgene Corporation; 2019 to present - Executive Vice President and Chief Financial Officer.

Mr. Gregory Scott Meyers, 2014 to 2018 - Corporate Vice President and Chief Information Officer, Motorola Solutions; 2018 to 2022 - Group Chief Information and Digital Officer, Syngenta Group; 2022 to present - Executive Vice President, Chief Digital and Technology Officer.

Mr. Theodore R. Samuels, Experience: President of the Capital Guardian Trust Company (2010-2016); Board member, Capital Group (2005-2009); Capital Group Audit Committee; Capital Group Finance Committee (2013-2016); Chair of Capital International (North America) Proxy Committee; Capital Guardian Trust Company (North American) Management Committee member; Portfolio Manager at Capital Group (1990-2016 and analyst 1981-1990). Other: Director of BJC HealthCare; Trustee of Children's Hospital Los Angeles Foundation; served as Director of Children's Hospital Los Angeles (2004-2019; co-chair 2012-2015); Director of the Edward Mallinckrodt, Jr. Foundation; Director of Research Corporation Technologies, Inc.; Trustee of the John Burroughs School, St. Louis (2018-2024); Co-Chair of Tuft's President Council (2016-2022). Other Public Company Boards: Centene Corporation; Iron Mountain Incorporated. Former Public Company Boards: Stamps.com; Perrigo Company plc.

Dr. Julia A. Haller, M.D., Experience: Chief Executive Officer and Ophthalmologist-in-Chief of Wills Eye Hospital in Philadelphia, PA, where she holds the William Tasman, M.D. Endowed Chair (2007-present, including appointment as CEO in 2025); Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals (present); Member of the Johns Hopkins faculty, where she held the Katharine Graham Chair in Ophthalmology (until 2007); Trained at the Wilmer Eye Institute at Johns Hopkins, where she served as the first female Chief Resident. Other: Vice President, Ophthalmology Foundation; Member of the National Academy of Medicine; Chair of the Heed Ophthalmic Foundation Board; Executive Committee of the Board of the Philadelphia Orchestra and Kimmel Center. Former Public Company Boards: Celgene Corporation; Eyenovia, Inc.; Opthea Limited; Outlook Therapeutics, Inc.

Ms. Paula A. Price, Experience: Executive Vice President and Chief Financial Officer at Macy's, Inc. (2018-2020); Senior Lecturer at Harvard Business School in the Accounting and Management Unit (2014-2018); Executive Vice President and Chief Financial Officer of Ahold USA (2009-2014); Senior Vice President, Controller and Chief Accounting Officer at CVS Caremark (2006-2009). Other: Director of Blue Cross Blue Shield of Massachusetts; Member of Advisory Board of Columbia University Mailman School of Public Health. Other Public Company Boards: Accenture plc; Warner Brothers Discovery; Mondelez International, Inc. Former Public Company Boards: Davita, Inc.; Dollar General Corporation; Western Digital Corporation.

Mr. Michael R. McMullen, Experience: Chief Executive Officer of Agilent Technologies, Inc. (2015-2024); President and Chief Operating Officer of Agilent Technologies, Inc. (2014-2015); Senior Vice President, Agilent and President, Chemical Analysis Group at Agilent (2009-2014). Other: Board of Trustees, University of Delaware (2024-present). Other Public Company Boards: KLA Corporation. Former Public Company Boards: Agilent Technologies, Inc.; Coherent, Inc.

Mr. Peter J. Arduini, Experience: President and Chief Executive Officer at GE Healthcare, a medical technology and digital solutions innovator (2022-present); President and Chief Executive Officer at Integra LifeSciences Holdings Corporation (2012-2021); President and Chief Operating Officer (2010-2012); Corporate Vice President and President of Medication Delivery, Baxter Healthcare (2005-2010); Previously spent 15 years at General Electric Healthcare in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Other: Board of Directors of AdvaMed (the Advanced Medical Technology Association); Board of Directors of the National Italian American Foundation; Board of Trustees of Susquehanna University (2016-2022). Other Public Company Boards: GE Healthcare. Former Public Company Boards: Integra LifeSciences Holdings Corporation.

Ms. Phyllis R. Yale, Experience: Advisory Partner, Bain & Company (2010-present); Partner (1987-2010); Since 1982, has served in a number of leadership roles and has been a leader in building Bain's healthcare practice. Other: Director of Aledade, Inc.; Member of the Advisory Board of the Health Policy and Management Department at the Harvard Chan School of Public Health; Member of the Board of The Trustees of Reservations, a conservation and preservation organization; Former director of Blue Cross Blue Shield of Massachusetts; Former member of the Advisory Board of Harvard Business School Healthcare Initiative. Other Public Company Boards: Davita, Inc.

Dr. Deepak L. Bhatt, M.D.,M.P.H., Experience: Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai (2022-present); Professor of Medicine at Harvard Medical School (2012-2022); Visiting Professor of Medicine at Harvard Medical School (2022-2024); Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital (2013-2022); Cardiologist at Dana Farber Cancer Institute (2009-2022); Chief of Cardiology at VA Boston Healthcare (2008-2013); Held a number of roles of increasing responsibility at the Cleveland Clinic in Cleveland, Ohio, in addition to being an attending physician, including Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center, Director of the interventional cardiology fellowship, and Associate Director of the cardiovascular medicine fellowship (2001-2008). Other: Former Member of the Board of Trustees of the American College of Cardiology.

Ms. Cari Gallman, 2015 to 2018 - Senior Counsel, US Legal; 2018 to 2019 - Assistant General Counsel, Oncology Legal; 2019 to 2021 - Vice President, Assistant General Counsel, Worldwide Oncology; 2021 to 2023 - Senior Vice President, Chief Compliance Officer; 2023 to 2025 - Executive Vice President, Corporate Affairs; 2025 to present - Executive Vice President, General Counsel and Chief Policy Officer.

Ms. Lynelle Hoch, 2016 to 2019- Vice President, Immuno-Oncology Marketing; 2019 to 2021 - General Manager, Ireland & UK, Major Markets; 2021 to 2023 - Senior Vice President, Global Cell Therapy Franchise Lead; 2023 to present - President, Cell Therapy Organization.

Ms. Karin Shanahan, 2013 to 2018 - Senior Vice President and Chief Operating Officer, Global Operations, Teva Pharmaceuticals; 2018 to 2022 - Senior Vice President, Global Biologics & Sterile Operations, Merck; 2022 to present - Executive Vice President, Chief Supply Chain & Operations Officer.

Ms. Amanda Ahn Poole, 2017 to 2019 - Vice President, Head of Human Resources, Global Product Development & Supply; 2019 to 2020 - Vice President, Head of BMS/Celgene Integration; 2020 to 2022 - Senior Vice President, Head of Human Resources, Commercialization; 2022 to 2024 - Senior Vice President, People Strategy, Solutions & Services; 2024 to present - Executive Vice President, Chief People Officer.

Ms. Wendy Short Bartie, 2021 to 2022 - Senior Vice President, U.S. Oncology; 2022 to 2023 - Senior Vice President, Chief of Staff to the CEO; 2023 to 2023 - Senior Vice President, General Manager, US Hematology and Cell Therapy; 2024 to 2025 - Senior Vice President, U.S. Oncology and Hematology; 2025 to 2025 - Senior Vice President, Oncology Commercialization; 2025 to present - Executive Vice President, Corporate Affairs.

Dr. Robert M. Plenge, 2017 to 2019 - Vice President Inflammation and Immunology, Thematic Center of Excellence Unit, Celgene Corporation; 2019 to 2021 - Senior Vice President, Immunology, Cardiovascular & Fibrosis, Thematic Research Center; 2021 to 2023 - Senior Vice President, Immunology, Cardiovascular & Fibrosis, Thematic Research Center, and Head of Translational Medicine; 2023 to 2023 - Senior Vice President and Head of Discovery and Translational Sciences; 2023 to present - Executive Vice President, Chief Research Officer, Head of Research.

Mr. Benjamin J. Hickey, M.B.A., 2014 to 2016 - Vice President, Commercial, Immuno-Oncology; 2016 to 2018 - General Manager, UK & Ireland; 2018 to 2020 - Senior Vice President, Chief Commercial Officer, Halozyme Therapeutics; 2020 to 2024 - Chief Commercial Officer, Head of Business Development, Mirati Therapeutics; 2024 to present - President, RayzeBio Organization, Bristol-Myers Squibb Company.

Mr. Hiroshi Chris Shibutani, M.D., 2015 to 2020 - Senior Analyst, Managing Director, Biotechnology Equity Research, Cowen; 2021 to 2025 - Senior Analyst, Managing Director, Pharmaceuticals & Biotechnology Equity Research, Goldman Sachs; 2025 to present - Executive Vice President, Chief Strategy Officer.

Sandra Leung, 2007 to 2014 - General Counsel and Corporate Secretary. 2014 to 2015 - Executive Vice President, General Counsel and Corporate Secretary, 2015 to present - Executive Vice President, General Counsel. On February 14, 2025, Sandra Leung notified Bristol-Myers Squibb Company (the Company) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.